After close of stock market?

Quote






why would you want to unload it? it will probably go up as stockholders will probably love the fact we are cutting overhead costs in marketing and sales. when tekturna disaster was announced our stock went up. why? because the financial analysts knew what all the reps knew, that the drug was not something the doctors felt they needed and was severely underperforming vs budget. so now novartis is going to reduce sales force by 60% which will save the company millions. its called addition by subtraction. wouldn't be surprised if the stock went up tomorrow after press release.
 






Anonymous said:
why would you want to unload it? it will probably go up as stockholders will probably love the fact we are cutting overhead costs in marketing and sales. when tekturna disaster was announced our stock went up. why? because the financial analysts knew what all the reps knew, that the drug was not something the doctors felt they needed and was severely underperforming vs budget. so now novartis is going to reduce sales force by 60% which will save the company millions. its called addition by subtraction. wouldn't be surprised if the stock went up tomorrow after press release.
Click to expand...

you're insane there is nothing to replace the revenue stream eroded by looming patent expirations & & there's still 30 billion in Alcon debt to repay
 












what you fail to realize is that a stock price is based on future earnings, profits, etc of the entire company not just primary care. analysts were never on board with the projections novartis had regarding aliskirin and everyone already knew about diovan losing patent protection so that was already built into stock price. the only big difference to the stock price would be the news regarding aliskirin and i don't see that killing the stock price. i was reading earlier where someone thought this was a good thing for novartis because they'll realize over $450 million in savings by 2013 (next year) by cutting the field force. tekturna sales totaled $449 million in first nine months last year and was NOT profitable. tekturna represented 2% of novartis pharma sales in 2011. to us its a much bigger deal because it is going to cost us our jobs. to the stock price it is merely a small bump (or possibly small boost depending on your view). the pipeline that is shaping up for 2014 is much more relevant to the stock price than losing an unprofitable drug that many analysts didn't like the potential of.
 






Top Bottom
Back
Quote